Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Zentalis Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ZNTL
Nasdaq
2834
https://www.zentalis.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- May 1st, 2024 9:30 pm
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
- Apr 2nd, 2024 8:05 pm
Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) Intrinsic Value Is Potentially 98% Above Its Share Price
- Feb 29th, 2024 10:50 am
Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet
- Feb 28th, 2024 2:55 pm
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
- Feb 28th, 2024 12:00 pm
Zentalis Pharmaceuticals Inc (ZNTL) Reports Full Year 2023 Financial Results and Provides ...
- Feb 28th, 2024 12:01 am
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
- Feb 27th, 2024 12:00 pm
Down -19.06% in 4 Weeks, Here's Why You Should You Buy the Dip in Zentalis Pharmaceuticals, Inc. (ZNTL)
- Feb 14th, 2024 2:35 pm
Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference
- Feb 13th, 2024 12:00 pm
What Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock
- Feb 8th, 2024 5:00 pm
Insider Sell: President Cam Gallagher Sells 11,552 Shares of Zentalis Pharmaceuticals Inc (ZNTL)
- Feb 6th, 2024 4:26 am
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
- Jan 25th, 2024 12:00 pm
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
- Jan 8th, 2024 12:00 pm
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans
- Dec 27th, 2023 10:07 am
David Johnson Bought 16% More Shares In Zentalis Pharmaceuticals
- Nov 16th, 2023 10:06 am
Director David Johnson's Strategic Purchase of Zentalis Pharmaceuticals Inc Shares
- Nov 14th, 2023 2:03 am
Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD Cowen
- Nov 9th, 2023 12:00 pm
Zentalis Pharmaceuticals Inc (ZNTL) Reports Q3 2023 Financial Results and Operational Updates
- Nov 7th, 2023 12:13 am
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
- Nov 6th, 2023 12:18 pm
Insider Sell: Chief Medical Officer Carrie Brownstein Sells 10,628 Shares of Zentalis ...
- Oct 7th, 2023 9:00 am
Scroll